bs-1355R **[Primary Antibody]**

TANK Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 8658 **SWISS:** O95271

Target: TANK

Immunogen: KLH conjugated synthetic peptide derived from human TANK: 151-260/425.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: TANK was initially identified as a novel TRAF-interacting protein that regulated TRAF-mediated signal transduction. Specifically, ligand binding by surface receptors in the tumor necrosis factor (TNF) receptor and Toll/interleukin-1 (IL-1) receptor families lead to the formation of a TRAF/TANK complex that mediates the activation of the transcription factor NF-kappaB. TANK is found in the cytoplasm and can bind to TRAF1, TRAF2, or TRAF3, thereby inhibiting TRAF function by sequestering the TRAFs in a latent state in the cytoplasm. For example, this protein can block TRAF2 binding to LMP1, the Epstein Barr virus transforming protein, and inhibit LMP1-mediated NF kappa B activation.

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse, Rat)

Predicted MW.: 48 kDa

Subcellular Location: Cytoplasm ,Nucleus

SELECTED CITATIONS

- **[IF=8.786]** Shasha Li. et al. TANK shapes an immunosuppressive microenvironment and predicts prognosis and therapeutic response in glioma. FRONT IMMUNOL. 2023; 14: 1138203 IHC ;Human. 37215097